Strategic Acquisition Opportunity The recent acquisition of Checkpoint Therapeutics by Sun Pharma for 355 million dollars indicates strong commercial interest and validates the company's oncology pipeline, presenting an opportunity for sales teams to position complementary or supporting products to Sun Pharma or similar large pharma companies.

Growth Potential in Oncology Checkpoint’s focus on accelerating the development and commercialization of cancer treatments through a streamlined approach suggests high market demand for innovative oncology solutions, providing avenues for partnering on supply, distribution, and drug development support.

Funding and Market Expansion With recent financing of 12 million dollars and ongoing drug development activities like the resubmission of the biologics license application for cosibelimab, there is potential for sales opportunities in supporting clinical trials, regulatory consulting, and drug manufacturing services.

Vulnerabilities & Litigation Multiple class action lawsuits filed against Checkpoint indicate potential stability concerns or reputational risk, creating an entry point for legal, compliance, or risk management advisory services to support the company’s operational stability during this period.

Innovative Technology Use Checkpoint's use of advanced technology stacks such as New Relic and Google Analytics demonstrates an emphasis on digital infrastructure, opening doors for cybersecurity, data analytics, and SaaS solutions to enhance their operational efficiency.